iBio, Inc.
iBio, Inc. (IBIO): 4 pipeline candidates · ~37 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
36.7 months
D/E 0.11 · 246% dilution
Lead: Phase 1
4 candidates
N/A
4 buys · 0 sells (180d)
A transparent, data-derived signal for iBio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$79.5M
Cash
$47.9M
Quarterly Burn
$6.1M
Runway
36.7 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| amylin receptor antibody | Preclinical |
| ibio-600 | Phase 1 |
| ibio-610 | Phase 1 |
| myostatin x activin a bispecific antibody | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$27.0M
| Holder | Shares | Value |
|---|---|---|
| affinity asset advisors, llc | 3,107,200 | $5.9M |
| vanguard capital management llc | 2,176,598 | $4.1M |
| millennium management llc | 1,549,850 | $2.9M |
| balyasny asset management l.p. | 1,010,955 | $1.9M |
| citadel advisors llc | 956,429 | $1.8M |
| walleye capital llc | 777,108 | $1.5M |
| marshall wace, llp | 620,602 | $1.2M |
| adar1 capital management, llc | 469,878 | $893K |
| susquehanna international group, llp | 412,725 | $784K |
| two sigma investments, lp | 408,858 | $777K |
Showing top 10 of 47 institutional holders of iBio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in iBio, Inc.'s pipeline?
iBio, Inc. (IBIO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is iBio, Inc.'s lead drug candidate?
iBio, Inc.'s most advanced tracked candidate is amylin receptor antibody (Preclinical) for Obesity.
What is iBio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, iBio, Inc. has approximately 36.7 months of cash runway.
What is iBio, Inc.'s market capitalization?
iBio, Inc.'s market capitalization is approximately $79.5M.
Who is the CEO of iBio, Inc.?
Dr. Martin B. Brenner D.V.M., Ph.D. is the chief executive officer of iBio, Inc. (IBIO).
Get the full picture on iBio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.